Visitors tour the Nvidia booth during the Nvidia Product Showcase at Computex 2026 in Taipei on June 3, 2026. AFP via Getty Images/I-Hwa Cheng A preprint published June 24, 2026, by 13 researchers at ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

Artificial intelligence has the potential to improve the analysis of medical image data. For example, algorithms based on deep learning can determine the location and size of tumors. This is the ...

Najat Khan looks at successful platform companies like Vertex, Regeneron and Alnylam and sees a path for Recursion to join them—if the company stays disciplined. (Recursion Pharmaceuticals) Chris ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

According to @_avichawla on Twitter, MIT researchers detail Recursive LLMs that call themselves to decompose tasks, verify intermediate steps, and iterate until convergence; as reported by MIT CSAIL ...

Speaking at WSJ Opinion Live in Washington, D.C., WSJ Editorial Page Editor Paul Gigot and SandboxAQ CEO Jack Hidary discuss Large Quantitative Models (LQMs) and their role in AI applications, the ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Recursion (RXRX). The reason why I want to go over this biotech next is because the company ...

The consensus mark for RXRX's Q4 loss and sales are pinned at 28 cents per share and $25.5M, respectively. In late 2025, RXRX highlighted REC-4881 data showing rapid, durable polyp reductions in FAP ...